NASDAQ:TAOX Synaptogenix (TAOX) Stock Price, News & Analysis $7.65 +1.20 (+18.60%) As of 08/22/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsSEC FilingsTrendsBuy This Stock About Synaptogenix Stock (NASDAQ:TAOX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Synaptogenix alerts:Sign Up Key Stats Today's Range$6.40▼$7.8850-Day Range N/A52-Week Range$1.84▼$11.98Volume337,606 shsAverage Volume279,270 shsMarket Capitalization$26.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York. Read More Receive TAOX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Synaptogenix and its competitors with MarketBeat's FREE daily newsletter. Email Address TAOX Stock News HeadlinesWall Street Zen Downgrades Synaptogenix (NASDAQ:TAOX) to SellAugust 19, 2025 | americanbankingnews.comSee More Headlines TAOX Stock Analysis - Frequently Asked Questions How have TAOX shares performed this year? Synaptogenix's stock was trading at $8.41 at the beginning of 2025. Since then, TAOX shares have decreased by 9.0% and is now trading at $7.65. How were Synaptogenix's earnings last quarter? Synaptogenix, Inc. (NASDAQ:TAOX) released its quarterly earnings results on Friday, August, 15th. The company reported ($11.26) earnings per share for the quarter. How do I buy shares of Synaptogenix? Shares of TAOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/15/2025Today8/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TAOX CIK1571934 WebN/A Phone(973) 242-0005FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)($20.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.77 million Net MarginsN/A Pretax MarginN/A Return on Equity-277.76% Return on Assets-150.79% Debt Debt-to-Equity RatioN/A Current Ratio20.52 Quick Ratio72.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.95 per share Price / Book1.55Miscellaneous Outstanding Shares3,490,000Free Float3,392,000Market Cap$26.70 million OptionableN/A Beta1.87 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:TAOX) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.